




Truist Securities Life Sciences AI Symposium – Biotech & Tools

March 1, 2022



Forward Looking Statements and Other Notices

This presentation may include forward-looking statements about, among other topics, Pfizer's digital strategy; our efforts to respond to COVID-19, including Comirnaty and Paxlovid; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications; our anticipated future operating and financial performance, business plans and prospects; our ability to successfully capitalize on growth opportunities and prospects; and other statements about our business, operations and financial results that are each subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results.

Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Potential risks and uncertainties also include the impact of COVID-19 on our sales and operations, including impacts on employees, manufacturing, supply chain, research and development, and clinical trials. The forward-looking statements in this presentation speak only as of the original date of the presentation and we undertake no obligation to update or revise any of these statements. This presentation is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. All trademarks in this presentation are the property of their respective owners.

4+1

Trends driving massive & rapid healthcare evolution

Patient Centricity



Patients are taking control of their care, looking for more personalization, access and convenience

Shift to Value



Shifting from volume to value to drive preventative care, greater access, and better health outcomes

Technology Breakthroughs



Digital is accelerating R&D, and novel technologies are increasing personalization and treatment options

New Disruptors



New entrants and intermediaries are reshaping the healthcare ecosystem from diagnostics to delivery



COVID-19 Acceleration



The pandemic has accelerated digital transformation exponentially, and at scale



Rather than creating a
DIGITAL STRATEGY
for our business...

We are creating a
BUSINESS STRATEGY
for a digital world.



Science-Driven

Pioneer **Breakthrough Innovations** to prevent, manage, treat or cure diseases using **cutting-edge science & technology**

Breakthroughs that change patients' lives

Patient-Centric

Change the lives of patients around the world by having significant impact that takes to the next level the current standard of care



Digital Innovation is Happening Across Our Entire Value Chain...

Discovery



Development



Manufacturing



Distribution




Engaging HCPs & Patients



analytics predictive data quantum computing automation
modeling algorithm sensors iot
machine learning tracking real-time cloud augmented technology
digital monitoring artificial intelligence remote


Supercomputing, AI and Advanced Analytics are Accelerating Discovery

Virtual in-silico lab reduces timeframes for very complex calculations by 80-90%, a factor of 5-10x acceleration.




Reduced research and discovery cycle time for Paxlovid™.

Minimized allergic reactions to the vaccine.



Delivered Paxlovid™ in pill form for at-home treatment.

Pfizer Launched an Unprecedented Clinical Trial



46,000

participants

150

sites



6

countries... in only **4** months.



Pfizer leveraged AI/ML to accelerate our Comirnaty trials...

- Performing quality-checks and analyzing vast amounts of trial data in record time, while maintaining quality and data integrity.
- Using real-time predictive models to determine where the next wave of the virus would migrate to optimize the clinical trial site selection.

Rapid Manufacturing Scale-up of 3B+ Doses in 2021

Digital, data and technology are powering manufacturing and distribution...



Digital Operations Center provides an end-to-end view of manufacturing, allowing us to predict issues and adjust in real-time.


Manufacturing Intelligence Platform uses AI/ML to predict throughput and yield to ensure we can meet global demand

Batch Tracker identifies bottlenecks and potential areas of risk in manufacturing.

End-to-end cold chain capabilities allow for real-time monitoring of shipments and temperatures anywhere in the world


Creating More Personalized, Engaging Patient and HCP Experiences

- Our customers want the same **quality of digital interactions** with us that they **experience in their own lives...**
- With COVID as a catalyst, we are **transforming our engagement model** to be more personalized, meaningful and effective in addressing customer needs and expectations.
- Through this evolving go-to-market model, we'll be able to **deliver breakthroughs faster than ever before.**



Science Will Win...and Digital is Helping Us Do it Faster

COMIRNATY®
(COVID-19 Vaccine, mRNA)



269

Days from when Pfizer announced plans to co-develop a COVID-19 vaccine with BioNTech, to the day we received FDA's EUA



3B+

Doses of COMIRNATY® manufactured in 2021

PAXLOVID™

120M



Courses expected to be developed in 2022

~40



Countries that have given emergency or conditional authorizations for Paxlovid™, for use with certain populations

“Without digital, we wouldn't be here today.”

– Albert Bourla



Margaret Keenan, first person in the world to receive the authorized Pfizer-BioNTech COVID-19 vaccine. Image: Jacob King/Getty

*Pfizer's oral treatment is not approved but is authorized for emergency use by the FDA to treat mild-to-moderate COVID-19 in high-risk patients 12+, weighing at least 40kg, with positive results of SARS-CoV-2 viral testing.

There's No Turning Back...

Improve Patient Health Outcomes



Enhancing diagnosis, treatment and adherence rates

Bring Medicines to Patients



Maximizing digital, AI, and automation across research, clinical development and manufacturing

Fuel Tomorrow's Breakthroughs



Simplifying and accelerating scientific research

...Continuing the Momentum